Global Glycated Haemoglobin Testing Market Size, Share, and COVID-19 Impact Analysis, Product Type (Laboratory-Based Analyzers, and Point of Care (POC) Analyzers), By End User (Hospitals, Physical Examination Institution, Research Institutions, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Glycated Haemoglobin Testing Market Insights Forecasts to 2035

• The Global Glycated Haemoglobin Testing Market Size Was Estimated at USD 239.12 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 8.74% from 2025 to 2035
• The Worldwide Glycated Haemoglobin Testing Market Size is Expected to Reach USD 601.20 Million by 2035
• Asia Pacific is Expected to Grow the Fastest during the Forecast Period.

The Global Glycated Haemoglobin Testing Market Size was Worth around USD 239.12 Million in 2024 and is Predicted to Grow to around USD 601.20 Million by 2035 with a compound annual growth rate (CAGR) of 8.74% from 2025 and 2035. Expanding into emerging markets with sizable and expanding patient populations with diabetes has significant potential opportunities for the glycated hemoglobin testing market.

Market Overview

The global industry that develops, produces, and distributes diagnostic instruments and services for determining blood levels of glycated hemoglobin (HbA1c) is known as the "glycated hemoglobin testing market." The average blood glucose level for the previous two to three months is provided by this test, which is an essential tool for diabetes diagnosis, monitoring, and treatment. Point-of-care testing equipment, laboratory-based analyzers, and related reagents are all part of the market, which helps medical professionals provide efficient diabetes care.

Increased R&D efforts in early diagnosis and effective disease management, the rise in the home healthcare market, the growing number of diabetic patients, the aging population, and technological developments in diabetes diagnosis are the main drivers of the glycated hemoglobin testing market. The growing number of obese people is another factor that increases the risk of diabetes and fuels the need for routine blood sugar monitoring tests, including glycated hemoglobin testing market.  

Report Coverage

This research report categorizes the glycated hemoglobin testing market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the glycated hemoglobin testing market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the glycated hemoglobin testing market. 

Driving Factors

The market is anticipated to expand due to the rise in the number of diabetics and rising awareness of POC HbA1c testing in emerging nations. Point-of-care (POC) devices have become more and more popular among patients and healthcare providers in the glycated hemoglobin testing sector. One of the main factors propelling the glycated hemoglobin testing market's expansion has been the rising incidence of diabetes cases worldwide. Rising diabetes prevalence, growing desire for early diagnosis, improvements in point-of-care technologies, and increased awareness of long-term glucose monitoring are some of the primary factors propelling the glycated hemoglobin testing market.   

Restraining Factors

The high expense of sophisticated diagnostic tools, the lack of adequate healthcare infrastructure in underdeveloped nations, and patients' and healthcare professionals' ignorance of the advantages of routine HbA1c testing are some of the obstacles facing the glycated hemoglobin testing the market.

Market Segmentation

The glycated hemoglobin testing market share is classified into product type and end user. 

• The laboratory-based analyzers segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the product type, the glycated hemoglobin testing market is divided into laboratory-based analyzers and point of care (POC) analyzers. Among these, the laboratory-based analyzers segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The increase in central lab testing prompted the use of laboratory-based analyzers. PoC equipment is gradually giving way to centralized clinical labs for traditional HbA1c testing due to they provide precise and standardized analysis of large sample volumes with low risks of mistakes and manual intervention.

• The hospitals segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the end user, the glycated hemoglobin testing market is divided into hospitals, physical examination institution, research institutions, and others. Among these, the hospitals segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The hospitals' comprehensive healthcare services, which include sophisticated diagnostic tools and integrated care models that support efficient diabetes control, are responsible for the present section.

Regional Segment Analysis of the Glycated Haemoglobin Testing Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the glycated hemoglobin testing market over the predicted timeframe.

North America is anticipated to hold the largest share of the glycated hemoglobin testing market over the predicted timeframe. North America's high rate of diabetes, sophisticated healthcare system, extensive use of cutting-edge diagnostic tools, and powerful presence of major industry participants are all factors contributing to the region's success. The study's main conclusions show that the US and Canada have the greatest demand for glycated hemoglobin testing services. North American consumers are particularly vulnerable to diabetes due to their active lives and busy work schedules, which cause them to eat poorly.

Asia Pacific is expected to grow at a rapid CAGR in the glycated hemoglobin testing market during the forecast period. The main causes of Asia Pacific expansion include the increased incidence of diabetes, rising healthcare costs, easier access to diagnostic tools, and expanding knowledge of diabetic care. The introduction of point-of-care testing and improvements in healthcare infrastructure are also fueling the region's explosive market growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the glycated hemoglobin testing market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Abbott Laboratories
• Beckman Coulter, Inc.
• ARKRAY, Inc.
• Tosoh Corporation
• Roche Diagnostics
• Bayer AG
• Bio-Rad Laboratories, Inc.
• Alere Inc.
• Siemens Healthineers
• Randox Laboratories Ltd.
• F. Hoffmann-La Roche Ltd.
• A.Menarini Diagnostics Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In January 2024, A new HbA1c diagnostic tool was launched by Roche Diagnostics to increase the precision of diabetes diagnosis.  

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the glycated hemoglobin testing market based on the below-mentioned segments:  

Global Glycated Haemoglobin Testing Market, By Product Type

• Laboratory-based analyzers
• Point of Care (POC) analyzers

Global Glycated Haemoglobin Testing Market, By End User

• Hospitals
• Physical Examination Institution
• Research Institutions
• Others

Global Glycated Haemoglobin Testing Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa